Apatinib Plus Anti-PD1 Therapy for Advanced Osteosarcoma

Clinical trial NCT03359018 · COMPLETED

Trial details

NCT number: NCT03359018
Sponsor: Peking University People's Hospital
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Progression-free Survival Overall Survival Clinical Benefit Rate Toxicity

Start date: 2018-01-01
Primary completion: 2019-10-22
Enrollment: 43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.